Abbott (NYSE: ABT) announced today that it launched a next-generation delivery system for its neuromodulation business.

Abbott received a breakthrough device designation ... According to Dr Brian Kopell, director of the Center for Neuromodulation at Mount Sinai West and principal investigator of the trial, there ...

Abbott Neuromodulation's Jenn Wong discusses the TRANSCEND trial for depression, imaging tech advancing DBS and other ...

Abbott Laboratories' medical device business is executing well, with double-digit growth in structural heart and diabetes. Read why ABT stock is a Hold.

The market includes spinal cord stimulation (SCS) systems as well as peripheral nerve stimulation (PNS) systems - ...

Prior to the latest Abbott approval, people new to deep brain ... "We are committed to continued innovation in neuromodulation, developing ongoing advancements and efficiencies for physicians ...

neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott ...

as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park ...

neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...